Jansen J, Zwaan FE, Haak HL, te Velde J, Guiot HF, Sabbe LJ, Eernisse JG, Tricot GJ, van Rood JJ. Anti-thymocyte globulin treatment for aplastic anemia.
SCANDINAVIAN JOURNAL OF HAEMATOLOGY 1982;
28:341-51. [PMID:
7051265 DOI:
10.1111/j.1600-0609.1982.tb00536.x]
[Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
20 patients with severe aplastic anemia were treated with anti-thymocyte globulin (ATG), 6 of them in combination with haplo-identical bone marrow. 7 patients (35%) showed a good clinical response within 6 months; they were off transfusions and had greater than or equal to 0.8 x 10(9)/l neutrophils. ATG had the greatest effect on red-cell production and the least on platelet production. The hematological recovery with ATG could not be predicted from the bone-marrow histology, CFU-c growth, or clinical data. However, patients with strong HLA antibodies seemed to respond more often. The actuarial survival was 55% at 5 years. Under intensive supportive care, even 7 out of 12 non-responders were alive after 1 year. ATG appears to be a useful form of therapy for patients with severe aplastic anemia who are not candidates for bone-marrow transplantation.
Collapse